Suppr超能文献

治疗性大剂量维生素 D 治疗维生素 D 缺乏的严重 COVID-19 疾病:随机、双盲、安慰剂对照研究(SHADE-S)。

Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S).

机构信息

Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

J Public Health (Oxf). 2024 May 29;46(2):256-266. doi: 10.1093/pubmed/fdae007.

Abstract

BACKGROUND

efficacy of therapeutic cholecalciferol supplementation for severe COVID-19 is sparingly studied.

OBJECTIVE

effect of single high-dose cholecalciferol supplementation on sequential organ failure assessment (SOFA) score in moderate-to-severe COVID-19.

METHODS

participants with moderate to severe COVID-19 with PaO2/FiO2 ratio < 200 were randomized to 0.6 million IU cholecalciferol oral (intervention) or placebo.

OUTCOMES

primary outcome was change in Day 7 SOFA score and pre-specified secondary outcomes were SOFA and 28-day all-cause mortality.

RESULTS

in all, 90 patients (45 each group) were included for intention-to-treat analysis. 25(OH)D3 levels were 12 (10-16) and 13 (12-18) ng/ml (P = 0.06) at baseline; and 60 (55-65) ng/ml and 4 (1-7) ng/ml by Day 7 in vitamin D and placebo groups, respectively. The SOFA score on Day 7 was better in the vitamin D group [3 (95% CI, 2-5) versus 5 (95% CI, 3-7), P = 0.01, intergroup difference - 2 (95% CI, -4 to -0.01); r = 0.4]. A lower all-cause 28-day mortality [24% compared to 44% (P = 0.046)] was observed with vitamin D.

CONCLUSIONS

single high-dose oral cholecalciferol supplementation on ICU admission can improve SOFA score at Day 7 and reduce in-hospital mortality in vitamin D-deficient COVID-19. ClinicalTrials.gov  id: NCT04952857 registered dated 7 July 2021. What is already known on this topic-vitamin D has immunomodulatory role. Observational and isolated intervention studies show some benefit in COVID-19. Targeted therapeutic vitamin D supplementation improve outcomes in severe COVID-19 is not studied in RCTs. What this study adds-high-dose vitamin D supplementation (0.6 Million IU) to increase 25(OH)D > 50 ng/ml is safe and reduces sequential organ failure assessment score, in-hospital mortality in moderate to severe COVID-19. How this study might affect research, practice or policy-vitamin D supplementation in vitamin D-deficient patients with severe COVID-19 is useful may be practiced.

摘要

背景

治疗性胆钙化醇补充治疗严重 COVID-19 的疗效研究甚少。

目的

研究单次大剂量胆钙化醇补充对中重度 COVID-19 序贯器官衰竭评估(SOFA)评分的影响。

方法

将中重度 COVID-19 且 PaO2/FiO2 比<200 的患者随机分为 0.6 百万 IU 胆钙化醇口服(干预)或安慰剂组。

结局

主要结局为第 7 天 SOFA 评分的变化,预设的次要结局为 SOFA 和 28 天全因死亡率。

结果

共有 90 例患者(每组 45 例)纳入意向治疗分析。维生素 D 组和安慰剂组的 25(OH)D3 水平分别为 12(10-16)和 13(12-18)ng/ml(P=0.06),第 7 天分别为 60(55-65)和 4(1-7)ng/ml。维生素 D 组第 7 天的 SOFA 评分更好[3(95%CI,2-5)比 5(95%CI,3-7),P=0.01,组间差异-2(95%CI,-4 至-0.01);r=0.4]。维生素 D 组 28 天全因死亡率较低[24%比 44%(P=0.046)]。

结论

在 ICU 入院时给予单次大剂量口服胆钙化醇补充可改善第 7 天的 SOFA 评分,并降低维生素 D 缺乏的 COVID-19 患者的住院死亡率。ClinicalTrials.gov 注册号:NCT04952857,登记日期:2021 年 7 月 7 日。关于这一主题,目前已知的内容是:维生素 D 具有免疫调节作用。观察性和孤立性干预研究表明 COVID-19 有一定益处。针对 COVID-19 的靶向治疗性维生素 D 补充改善结局的 RCT 研究尚未开展。本研究的新发现是:补充大剂量维生素 D(0.6 百万 IU)以增加 25(OH)D>50ng/ml 是安全的,可降低中重度 COVID-19 的序贯器官衰竭评估评分和住院死亡率。本研究对研究、实践或政策可能产生的影响是:维生素 D 缺乏的严重 COVID-19 患者补充维生素 D 可能是有用的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验